Safe Harbor Statement

Transcription

1 1

2 Safe Harbor Statement This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson s Annual Report on Form 10-K for the fiscal year ended January 2, Copies of this Form 10-K, as well as subsequent filings, are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments. 2

3 Note on Non-GAAP Financial Measures These presentations may refer to certain non-gaap financial measures. These non-gaap financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-gaap financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company s website at 3

4 4

5 Alex Gorsky Vice Chairman, Executive Committee Office of the Chairman 5

6 Rapidly Evolving Industry Dynamics Favoring Johnson & Johnson Demographics/aging population Global expansion/ emerging markets Significant unmet medical needs Advancing science and technology Tailwinds 6

7 Rapidly Evolving Industry Dynamics Favoring Johnson & Johnson Headwinds Demographics/aging population Global expansion/ emerging markets Significant unmet medical needs Advancing science and technology Continued high unemployment in U.S. Austerity measures in Europe Declines in health care utilization Regulatory pressures Pricing and reimbursement pressures Tailwinds 7

8 We Participate in a Large Majority of the $350B MD&D Market Overall MD&D Market CAGR ( ) 4.9% 54% OUS 46% U.S. 37% Non-J&J Markets 63% J&J Markets Market Segments listed above do not include certain minor categories such as Non Electrical Diagnostics, IV Solutions, healthcare IT and other minor markets Source: Health Research International, Internal Estimates Adjustment made to Vision Market Definition (No longer includes Back of the Eye segment, currently treated with Pharmaceutical Treatments) 8

9 MD&D First-Half Performance YTD Sales: $13.0B, +1.3% $3.0B +2% $2.5B +4% $2.5B +2% FAMILY OF CARDIOVASCULAR COMPANIES $1.5B +4% $1.3B +6% $1.2B (12%) $1.1B +2% All % Operational 9

10 Seven Franchises, Twenty Major Platforms FAMILY OF CARDIOVASCULAR COMPANIES Electrophysiology Endovascular Cardiac Stents Knees Hips Spine SMBG Insulin Delivery Sutures Biosurgicals Aesthetics Endoscopy Mechanical Energy Diagnostics Contact Lenses Neuroscience Sports Medicine ENT Infection Prevention Sustaining/Gaining Share in Three-Quarters of Top Platforms 10

11 Strategic Priorities Innovative Products Robust Pipeline Geographic Presence Global Leadership and Talent Thomas Buehler Living free of atrial fibrillation 11

12 Innovative Products Contact Lenses 1 DAY ACUVUE Family of Lenses Gaining share in fast-growing daily disposable segment 12

13 Innovative Products SMBG OneTouch Verio Highly accurate, easy-to-use blood glucose monitoring system 13

14 Innovative Products Electrophysiology CARTO 3 and THERMOCOOL SMARTTOUCH Contact Force Sensing Catheter Advancing the treatment of atrial fibrillation 14

15 Innovative Products Biosurgicals SURGIFLO Hemostatic Matrix Kit EVICEL Fibrin Sealant Gaining Share in Biosurgicals 15

16 Innovative Products Ear, Nose, and Throat CYCLOPS Multi-Angle Endoscope Provides a comprehensive view of the nasal cavity 16

17 Strategic Priorities Innovative Products Robust Pipeline Geographic Presence Global Leadership and Talent Paul Andrews and Carrole White Using GLOSAIR TM to reduce infections 17

18 Pending Pending Approved/Cleared Approved/Cleared 2010 Planned Submissions 2010 Planned Submissions 2011 Planned Submissions 2011 Planned Submissions 2012 Planned Submissions 2012 Planned Submissions Cordis NEVO Coronary Stent (CE Mark) EXOSEAL VCD (PMA) CARTO Xpress Navigation Technology (510(k)) CARTO 3 Navigation Technology (Japan & China) THERMOCOOL SF Irrigated Catheter (PMA) CYPHER Coronary Stent 4.0 (PMA) CYPHER Xtend Extended Dating (PMA Supp) THERMOCOOL SMARTTouch Contact Force Catheter (CE Mark) DePuy CoMplete Acetabular Hip System GRIPTION TF (TIFOAM)* Hip and Knee AOX Poly for Sigma and LCS Affixus Hip Fracture Nail* MEDSTREAM * Programmable Pump Diabetes Care Diabetes High Accuracy Blood Glucose System Version 1 Ethicon SURGIFLO with Integrated Thrombin Kit (EU) DERMABOND Topical Skin Adhesive New Formulation Cordis CYPHER Coronary Stent 2.25 (PMA Supp) EXOSEAL VCD (CE Mark) CARTO 3 Navigation Technology (510(k) & CE Mark) CARTO 3 Diagnostics Catheter Portfolio (510(k) & CE Mark) NAVISTAR THERMOCOOL Afib Indication (PMA) THERMOCOOL SF Irrigated Catheter (CE Mark) PRESILLION Plus Bare Metal Stent (CE Mark) CYPHER SELECT Plus Stent (Japan) DePuy ASPHERE * Contoured Metal Heads TRUMATCH * Personalized Solutions Sigma CR150* Mobile Bearing A.L.P.S. System Modules* (Anatomic Fibula, Anatomic Elbow, Proximal Tibia) COUGAR LS Lateral Cage ScoliScore AIS Prognostic Test* GRYPHON BR ANCHOR NEXTRA System ORBIT GALAXY Detachable Embolic Coil* Diabetes Care ONETOUCH Ping (Canada) Diabetes High Accuracy Blood Glucose System (CE Mark) Ethicon PROCEED Ventral Patch (EU) PDS Plus Antibacterial (polydioxanone) Suture (EU) PDS Flexible Plates (U.S. & EU) SURGIFLO with Integrated Thrombin Kit NUVANCE Facial Rejuvenation System (EU) PREVELLE Lift Dermal Filler (EU) ETHICON SECURESTRAP 5mm Strap Fixation Device ETHICON PHYSIOMESH Flexible Composite Mesh MENTOR Sensitive Anatomical Gel (EU) GYNECARE MORCELLEX Re- Launch GYNECARE PROSIMA Pelvic Floor Repair System GYNECARE TVT EXACT Continence System ETHICON OMNEX Surgical Sealant Ethicon Endo Echelon Flex 60mm Stapler ENSEAL Advanced Bipolar Shears Ethicon Endo-Surgery LINEAR CUTTER and Selectable Cartridges/Reloads Curved & Straight Intraluminal Staplers HARMONIC FOCUS Long Curved Shears ECHELON FLEX 45mm Stapler HARMONIC ACE Curved Shears with Ergo Handle (ACE45E) SEDASYS System (Canada & EU) OCD VITROS 5600 System + VITROS 3600 System VITROS Assays CELLEX Photopheresis System ORTHO VERSEIA Pipettor Vision Care 1-DAY ACUVUE MOIST for ASTIGMATISM 1-Day Acuvue TruEye Cordis CARTO 3 V2 Navigation Technology (510(k) & CE Mark) PTA Balloons Next Generation (510(k) & CE Mark) THERMOCOOL SF Irrigated Catheter (Japan) DePuy RECLAIM Hip Revision Next Generation DVR Wrist Plate* Shoulder Fracture Platform CONFIDENCE Spinal HARMONIC /ENSE STERRAD Solution Cement System AL Combo DePuy Expansion LX TLIF Cage Generator MD&D Pipeline Highlights Next Generation GLOSAIR Area EXPEDIUM LX Endopath XCEL Knee System Decontamination 5mm with Solution VIPER LX OPTIVIEW Bone Preserving Hip Technology Stem OCD TLIF Cage 3/4 Have Progressed HARMONIC VaprVue & New Poly Hip Bearings New VITROS Coolpulse 90 Diabetes Care Integrated Continuous Glucose Monitor/Insulin Pump (PMA & CE Mark) Diabetes High Accuracy Blood Glucose System Version 2 Ethicon EVERPOINT Cardiovascular Needles Fibrin Pad (BLA) GYNECARE TVT ABBREVO Continence System GYNECARE V- Support Treatment Project Acclarent CYCLOPS Multi- Angle Endoscope Acclarent RELIEVA LUMA II Catheter Ethicon Endo ENSEAL Curved Open Shears SYNERGY Combination Hook Blade STERRAD Solution Expansion OCD ORTHO VERSEIA Pipettor Assays New VITROS Assays: - Intact parathyroid hormone - Hepatitis B e- antigen and antibody VITROS 4600 System 1 Vision Care Anti-allergy drug with a contact lens Cordis CARTO 3 V3 Navigation Technology (510(k) & CE Mark) THERMOCOOL SMARTTouch Contact Force Catheter (PMA & Japan) INCRAFT AAA Stent Graft (CE Mark) PRESILLION Plus Bare Metal Stent (PMA) S.M.A.R.T. Stent for SFA (PMA Supp) PTCA Balloon Next Generation (PMA & CE Mark) DVR Express WW Screw Platelet Rich Plasma System Ethicon Fibrin Pad (EU) VICRYL RAPIDE Plus Suture GYNECARE SUI Sling Next Generation PurTox Highly Purified Botulinum Neurotoxin Ethicon Endo ECHELON Next Gen Device ENSEAL Next Gen Bipolar Lap Shears HARMONIC Next Gen Ortho HARMONIC Next Gen Plastics Assays - HIV Combo 2 - Prostate-specific antigen 2 (PSA and Free PSA) - Syphilis Cordis NEVO Coronary Stent (PMA & Japan) EXOSEAL VCD (Japan) INCRAFT AAA Stent Graft (PMA & Japan) Circular Ablation (PMA & CE Mark) Next Gen NEVO Coronary Stent (PMA & CE Mark) DePuy DeltaMotion Hip System* Hip Bearings Hip Resurfacing System Next Generation Hip System Next Generation Shoulder CAIS Cartilage Regeneration Ethicon ETHICON Next Generation Wound Closure Project Mentor Becker Round Adjustable Gel GYNECARE Next Generation Pelvic Floor Repair Project Ethicon Endo Metabolics Next Gen MIS Next Gen Energy Solutions Next Gen Stapling STERRAD Solution Expansion Next Gen High- Level Disinfection OCD New VITROS Assay: Vitamin D VITROS 5300 System Transfusion Medicine Platform CELLEX System: Crohn s Disease and Graft-versushost disease Advanced Cellular Diagnostics Molecular Diagnostics Next Generation: Circulating Tumor Cell Platform Selective Highlights as of 6/3/10. Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company s knowledge. Johnson & Johnson assumes no obligation to update this information 1 Regulatory submission based on FDA filing for current platforms 2 PMA + VITROS 5600 System approved 10/08; VITROS 3600 System approved 12/08; Both launched

19 Robust Pipeline Energy Advanced Energy Generator First-of-its-kind system powering ultrasonic and advanced bipolar technologies ENSEAL G2 Super Jaw First bipolar advanced energy technology offering strong seals, while remaining gentle on tissue 19

20 Robust Pipeline Infection Prevention GLOSAIR Healthcare Environmental Decontamination System Reduces the risk of healthcareassociated infections 20

21 Robust Pipeline Insulin Delivery Animas Vibe Waterproof insulin pump integrated with continuous glucose monitoring system 21

22 Robust Pipeline Sedation SEDASYS System World s first computer-assisted personalized sedation system 22

23 Strategic Priorities Innovative Products Robust Pipeline Geographic Presence Global Leadership and Talent Paul Andrews and Carrole White Using GLOSAIR TM to reduce infections 23

24 Strategic Priorities Innovative Products Robust Pipeline Geographic Presence Global Leadership and Talent Dr. Zhao Zhongliang Improving lives in China 24

25 Geographic Presence: BRIC Markets Russia 1992 China 1985 India 1957 Brazil 1937 Johnson & Johnson BRIC market Presence Brazil 1937 India 1957 China 1985 Russia

26 Asia-Pacific Innovation Center Developing market-appropriate products for China and India 26

27 DePuy Institute Chennai, India Training orthopaedic surgeons in the latest techniques and technologies 27

28 Strategic Portfolio Management Enabled by Breadth and depth of businesses Financial strength Attractiveness as partner 28

29 Strategic Portfolio Management in Recent Years Exit non-core businesses Professional Wound Care, Breast Care Strengthen portfolio via acquisitions Acclarent, Finsbury, Gloster Europe, Micrus, Mentor, Omrix, SurgRx 29

30 Realigning Cardiovascular Care Franchise for Growth Exiting DES due to changing market dynamics Placing greater focus on remaining businesses Biosense Webster in Electrophysiology Cordis in Endovascular and Core Cardiology Exploring opportunities to expand into new market segments 30 30

31 A Compelling Combination: Opportunity to help millions of patients around the world Attractive global market Highly complementary portfolios Enhance long term growth Trauma Craniomaxillofacial Spinal Disease Power Tools 31 31

32 Key Takeaways Large attractive market, leadership presence Launching innovative products Investing in a robust pipeline Expanding global reach and capabilities Disciplined portfolio approach to maximize performance Talented people 32

33 33